The generic version of Ozobax is projected to be released after August 30, 2039. This estimate accounts for the expiration date of the drug's last patent, US10610502, titled 'Oral baclofen solutions'.
Ozobax is used to manage spasticity, a condition that causes muscles to stiffen and tighten without control. The drug’s active ingredient, baclofen, works by blocking nerve signals to muscles, thereby reducing muscle tension and improving movement.
Ozobax has a single patent, US10610502, titled 'Oral baclofen solutions'. This patent is set to expire on August 30, 2039, after which the Ozobax generic may become available. Below are the details of the patent: